

Original Research Article

<http://dx.doi.org/10.20546/ijcmas.2016.501.059>

## Antibiotic Associated Diarrhea and Incidence of *Clostridium difficile* Infection and Colonization in Infants and Children in Tanta University Hospital, Egypt

Marwa Ahmed Ali Abd El-Wahab<sup>1\*</sup>, Ahmed Mohamed Naeem<sup>2</sup>, Abd EL-Rahman Mohamed EL-Mashad<sup>2</sup> and Nehad Refhat Mostafa Sallam<sup>2</sup>

<sup>1</sup>Department of Microbiology and Immunology, Faculty of Medicine, Tanta, Egypt

<sup>2</sup>Department of Pediatrics, Faculty of Medicine, Tanta, Egypt

\*Corresponding author

### ABSTRACT

#### Keywords

CDAD,  
*C. difficile*  
toxins,  
*C. difficile*  
colonization,  
Stool culture,  
Egypt

#### Article Info

Accepted:  
25 December 2015  
Available Online:  
10 January 2016

Injudicious use of antibiotics in hospitalized patients increases the risk of *Clostridium difficile* associated diarrhea (CDAD). This study was conducted to determine the incidence of *C. difficile* as a cause of antibiotic associated diarrhea in pediatric patients in our hospital. Sixty infants and children with a history of antibiotic intake whether having diarrhea or not and 30 age and sex matched patients with no history of antibiotic intake were studied prospectively over a period of one year. Stool samples were processed for *C. difficile* isolation and examined for *C. difficile* toxin A and B by the enzyme-linked immunosorbent assay. 26 out of 60 cases (43.3%) suffered from diarrhea. Only (22/60) showed positive stool culture for *C. difficile*, 18 out of them had diarrhea while the remaining 4 patients had no diarrhea and only colonized with toxigenic *C. difficile* representing 11.8% of total 34 cases without diarrhea. Toxin A and B were detected in 16 patients including 4 asymptomatic carriers and 12 out of 26 cases with diarrhea representing 46.2%. The incidence of CDAD in our hospital was 46.2%. The asymptomatic carriage rate was 11.8%.

### Introduction

Extensive and widespread use of broad spectrum antibiotics has increased dramatically in the last decade especially in hospitalized patients. Despite their benefits in treating a lot of human infections, they are incriminated in changing the function and the composition of the intestinal microbiota causing what is called antibiotic associated diarrhea which ranges from mild, benign and self limiting diarrhea up to

severe life threatening colitis (Kaneria and Paul, 2012; Hurley and Nguyen, 2002; Kyne et al., 2002; Ferri, 2010).

The disruption happened in the intestinal flora may result in subsequent *Clostridium difficile* (*C. difficile*) colonization and infection especially in hospitalized patients (Hung et al., 2014; Wilcox, 2003). *C. difficile* is responsible for about 20% of all

cases of antibiotic associated diarrhea and the antibiotic use is considered as the most important risk factor for *C. difficile* associated diarrhoea (CDAD)(Voth and Ballard, 2005; Kaneria and Paul, 2012).

*Clostridium difficile* toxins A and B are mainly the cause of CDAD in infected patients (Knecht et al., 2014). *C. difficile* infection is classified by CDC as major public health problem that requires urgent attention (CDC, 2013).

*C. difficile* was first described in 1935 when it was isolated from stool of healthy individuals so it was classified as commensal (Hall and O'Toole, 1935), it was not known to be a cause of diarrhea until 1978 (Larson et al., 1987).

Infections by *C. difficile* are about to be doubled in the last decade. (Zilberberg et al., 2008<sub>a,b</sub>; Sharland et al., 2011). Although the rate and severity of *C. difficile* infections (CDIs) have increased, it is not well estimated as a reason for diarrhea in pediatric patients less than 18 years old (Pokorn et al., 2008; Kim et al., 2012). The main cause for such underestimation is that the asymptomatic carriage rate in pediatrics is considered high about (21-48%) in neonatal period and early infancy (Hung et al., 2015) and up to 8.3% of children older than two years of age (Cerquetti et al., 1995).

Although some patients are only carriers for *C. difficile* with no symptoms they are prone to develop CDI and diarrhea and are considered as a source for CDI as they are associated with skin and environmental contamination and representing a burden for the health care system, thus attention should be paid to such carriers due to their serious clinical importance (Hung et al., 2015).

However CDAD is still not well estimated in Egypt especially in pediatric patients because the anaerobic cultivation of stool samples is not a routine in our country and is somewhat considered expensive. Therefore we undertook a prospective study to assess the incidence of CDAD and asymptomatic carriers in hospitalized non-newborn infants and children received antibiotics for more than 10 days duration admitted to our hospital.

### **Materials and Methods**

This study was conducted prospectively over one year from August 2014 to September 2015 on 60 non-newborn infants and children with mean age (49.6±31) months, 50% males and 50% females on antibiotics including (Penicillins, aminoglycosides, cephalosporins, carbapenems, clindamycin, quinolones) whether had diarrhea or not and 30 age and sex matched controls with no antibiotic intake admitted to Department of Pediatrics at Tanta University hospital in Egypt. Patients with other infective causes of diarrhea (amoebiasis, acute gastroenteritis, enteric fever, hepatitis A), inflammatory bowel disease, irritable bowel syndrome and other causes of chronic diarrhea were excluded.

A detailed case history including age, sex, type of feeding and duration of antibiotic therapy were collected from patients' medical records. Written consent was taken from parents of each patient

Stool samples were collected in sterile wide mouthed sealed containers from all the studied cases and control and transferred immediately to Microbiology laboratory at faculty of Medicine, Tanta University, Egypt and the samples were processed immediately. All stool samples cultured

anaerobically on cefoxitin-cycloserine fructose agar (CCFA) (Biomerieux, France). Colonies grown on CCFA plate were presumptively identified as *C. difficile* were subjected to biochemical reactions. The remaining part of all stool samples were then stored at -80°C for further detection of *C. difficile* A and B toxins using ELISA kit (Supplied by Diagnostic Automation, Cortez Diagnostics, Inc., USA)

### **Processing of the Samples**

Stool samples were mixed in a ratio 1:1 with PBS to be homogenized and then heat shocked (80°C for 10 min.). Samples then centrifuged (at 4000x g for 1 min.)

### **Isolation and Identification of *C. difficile***

Culture: 1-2 drops from the supernatant were streaked onto CCFA to obtain single colonies. The plates were then incubated in anaerobic gas pack jar at 37 °C for 48-72 h using anaerobic air pack (Oxoid, UK).

On CCFA, circular, yellow, fimbriate colonies of 4mm size or larger, Gram positive bacilli with subterminal oval spores having horse stable odour was presumptively identified as *C. difficile*.

Colonies morphologically resembling the organism were confirmed by biochemical reactions (Willis, 1977; Jousimies-Somer et al., 2002).

### **Toxin Testing by ELISA**

Detection of toxins A and B of *C. difficile* was performed using *C. difficile* Toxin A+B 2nd Generation ELISA Kit according to the manufacturer's instructions. The results were read spectrophotometrically at 450 nm wavelength.

### **Statistical Analysis**

Statistical presentation and analysis of data in the present study was conducted using the mean, standard deviation and Chi-square test by SPSS V.16. P value of  $\leq 0.05$  indicated statistical significance.

### **Results and Discussion**

Stool samples of 60 non neonate infants and children cases received antibiotics and 30 control patients with no history of antibiotic intake were collected over the period of the study. Demographic, clinical and laboratory data of the studied group and their controls were summarized in table 1.

The specimens collected from the cases and cultured on CCFA were classified as positive and negative according to *C. difficile* isolation and compared in table 2.

The percentage of *C. difficile* and their toxins among the studied cases with or without diarrhea were illustrated in table 3.

Antibiotic administration in the studied cases with positive and negative stool cultures was illustrated in table 4.

*C. difficile* is a gram positive anaerobic sporulating rods that causes a variety of clinical presentations ranging from asymptomatic carrier state, mild diarrhea to severe debilitated disease that may be fatal in some cases (Beaulieu et al., 2007; Vaishnavi, 2010).

Antibiotic is considered the well known risk factor for CDAD (Kanerla and Paul, 2012). *C. difficile* causes diarrhea through secretion of exotoxins (A, B) that are responsible for the pathogenicity and disease production (Voth and Ballard, 2005).

The scope of the present study includes the isolation of *C. difficile* by culture, identification of *C. difficile* colonies by biochemical reactions, detection of toxins A and B by ELISA among pediatric patients with diarrhoea and thereby detecting the incidence of CDI in the studied group.

CDAD is still not well recognized in Egypt due to lack of clinical suspicion, cost of the toxin assay and difficulty in culturing the organism. Therefore we undertook a prospective study to determine the incidence of CDAD in our hospital.

Among 60 infants and children previously treated with antibiotics for 10 days or more, 26 cases (43.3%) showed clinical diarrhea, 22 cases (36.7%) had positive stool culture for *C. difficile*, and 16 cases (26.7%) showed *C. difficile* toxins in stools by ELISA. Our results were somewhat higher than the study done by Justin et al. (2015) who reported that (15.22%) of samples were culture positive for *C. difficile* and only (10.87%) of isolates from cases with diarrhea were positive for *C. difficile* toxins A and B by EIA. The higher incidence of toxic isolates in our study may be due to the presence of four cases from total 16 with toxigenic *C. difficile* were on antibiotics but had no diarrhea.

None of the control infants and children had diarrhea and all of them were negative for *C. difficile* organism and toxin. The difference between case and control was significant, indicating significant relationship between antibiotic administrations and *C. difficile* diarrhea or colonization. (table1)

These results agreed with the study performed by Levy (2000) who reported that antibiotics lead to increased susceptibility to the acquisition of *C. difficile*. Similarly, McFarland (1998) reported that diarrhea is a

common complication of antibiotics which occurs in between 5% to 39% of patients. This effect is caused by disturbance of the normal balance of intestinal organisms.

On the other hand our results disagreed with Wistrom et al. (2001) who stated that antibiotic associated diarrhea can occur up to 2-3 weeks following cessation of antibiotic therapy rather than during the treatment. The same was reported by Niyogi et al. (1991) who stated that *C. difficile* cytotoxin has been reported in 7% of studied patients, in a hospital in Calcutta, who did not had prior antibiotics.

In this study toxin was detected in 12 out of 26 cases with diarrhea so the incidence of CDAD was (46.2%). These findings were much higher than results obtained by Kaneria and Paul (2012) & Turck et al. (2003) who reported that the incidence of CDAD in their hospital was 10% and 11% respectively. Turck et al. (2003) study included children in outpatient setting and this may be the cause of this big difference between their results and ours as CDAD is primarily acquired from the hospital environment, which leads to the higher incidence noted in hospitalized patients who are treated with antibiotics, compared with those in outpatient settings .

The results of the current study were somewhat higher than Gupta et al. (1985) who isolated *C. difficile* from 25.3% of hospitalized patients with diarrhea. Also, Vaishnavi et al. (1999) reported 30% positivity for *C. difficile* toxin in hospitalized patients of all age groups receiving antibiotics for various diseases. Moreover, McFarland (2007) reported that *C. difficile* associated diarrhea was the etiology of 30% of all studied pediatric patients with diarrhea.

**Table.1** Demographic, Clinical and Laboratory Data of the Studied Cases and their Controls

	Cases (antibiotic intake)		Controls (No antibiotic intake)		X <sup>2</sup> test	p-value
	No.	%	No.	%		
Total	60	100%	30	100%		
Age (months) mean ±SD	49.6±31		25.6±21.4		0.335	0.739
Sex						
Male	30	50.0%	16	53.3%	0.044	0.833
Female	30	50.0%	14	46.7%		
Mode of delivery						
NVD	40	66.7%	16	53.3%	0.756	0.384
C.S	20	33.3%	14	46.7%		
Type of feeding						
Breast feeding	24	40.0%	8	26.7%	4.093	0.129
Artificial feeding	22	36.7%	6	20.0%		
Food	14	23.3%	16	53.3%		
Stool Consistency						
Diarrhea	26	43.3%	0	0.0%	9.141	<b>0.002**</b>
No diarrhea	34	56.7%	30	100.0%		
Stool culture for <i>C. difficile</i>						
+ve	22	36.7%	0	0.0%	7.279	<b>0.007**</b>
-ve	38	63.3%	30	100.0%		
Toxin detected by ELISA						
+ve	16	26.7%	0	0.0%	4.14	<b>0.04*</b>
-ve	44	73.3%	30	100.0%		

This table showed that there was no statistically significant difference between studied cases and their controls as regards, age, sex, mode of delivery and the type of feeding. But there was a statistically significant relation between diarrhea and antibiotic intake ( $P < 0.05$ ). Also *C. difficile* detection by stool culture and the presence of their toxins in stools was significantly higher in the studied cases than their controls ( $P < 0.05$ )

**Table.2** Comparison between *C. difficile* Positive and Negative Cultures among the Studied Infants and Children Cases

	Cases				X <sup>2</sup> test	p-value
	Stool culture for <i>C. difficile</i>					
	+ve		-ve			
	No.	%	No.	%		
Total	22	100%	38	100%		
Sex						
Male	10	45.5%	20	52.6%	0.144	0.705
Female	12	54.5%	18	47.4%		
Type of feeding						
Breast feeding	6	27.3%	18	47.4%	1.968	0.374
Artificial feeding	8	36.4%	14	36.8%		
Food	8	36.4%	6	15.8%		
Stool Consistency						
Diarrhea	18	81.8%	8	21.1%	10.476	<b>0.001**</b>
No diarrhea	4	18.2%	30	78.9%		
Toxin detected by ELISA						
+ve	16	72.7%	0	0.0%	15.77	□ <b>0.001**</b>
-ve	6	27.3%	38	100.0%		
Duration of antibiotic therapy before inclusion in research (days) mean ±SD	15.3±5.8		14.9±6.6		0.158	0.270

This table showed that there was no statistically significant difference between *C. difficile* positive and negative cases among studied infants and children as regards, sex, type of feeding, type of diarrhea, frequency of diarrhea, age and duration of antibiotic therapy.

While *C. difficile* detection by culture and their toxins by ELISA among cases with diarrhea was significantly high when compared to cases without diarrhea after antibiotic intake (p<0.05)

**Table.3** The Percentage of *C. difficile* and their Toxins among the Studied Cases with or without Diarrhea

Culture on CCFA	Toxin detected by ELISA	Diarrhea		Culture on CCFA	Toxin detected by ELISA	No diarrhea	
		No=26	%			No=34	%
+ve (18)	+ve	12	66.6	+ve (4)	+ve	4	100.0
	-ve	6	33.3		-ve	0	0.0
-ve (8)	+ve	0	0.0	-ve (30)	+ve	0	0.0
	-ve	8	100.0		-ve	30	100.0

This table showed that 46.2% (12 out of 26) of patients with antibiotic associated diarrhea were infected by toxigenic *C. difficile* so the incidence of CDAD was (46.2 %).. While 4 out of the 34 cases with no diarrhea were colonized with toxigenic *C. difficile* and were considered as asymptomatic carriers representing (11.8%)

**Table.4** Antibiotic Administration in the Studied Cases with Positive and Negative Stool Cultures

Antibiotics	Stool culture				X <sup>2</sup> Mann-Whitney	p-value
	C. difficile +ve culture (total 22)		C. difficile -ve culture (total 38)			
	No.	%	No.	%		
Penicillins	22	100%	34	89.47%	1.24	0.27
Aminoglycosides	10	45.45%	16	53.33%	0.03	0.86
Cephalosporins	20	90.9%	30	78.94%	0.72	0.40
Carbapenems	4	18.18%	8	21.05%	0.04	0.85
Clindamycin	2	09.09%	4	10.52%	0.02	0.90
Quinolones	4	18.18%	8	21.05%	0.04	0.85

This table showed that penicillins, cephalosporins and aminoglycosides were the most commonly used antibiotics associated with CDI. Moreover, there was no statistically significant difference between studied cases with *C. difficile* positive and negative cultures and one type of antibiotics used

On the other hand results obtained by Wistrom et al. (2001), showed that *C. difficile* contributed to more than 55.4% of diarrheal inpatients from five Swedish hospitals with great variance among the hospitals themselves obtained as high as 62.5% of tested patients in one of the studied centers. These results are slightly higher than ours because the study was done on adult patients.

Our study also showed that 4 out of the 34 cases with no diarrhea were colonized with toxigenic *C. difficile* and were considered as asymptomatic carriers whose toxin levels were low and not sufficient to produce symptoms and representing (11.8%) (table 4).

This result was higher than results of Kaneria and Paul (2012) who reported that the toxigenic *C. difficile* asymptomatic carriage rate was 6%. This difference may be due to environmental considerations and different population factors.

The current study showed that there was no statistically significant difference between studied cases with *C. difficile* positive and

negative cultures and one type of antibiotics used.

These results agreed with McFarland (1998), who stated that the occurrence of antibiotic associated diarrhea varies greatly and is influenced by a number of factors other than the type of antibiotic used, including nosocomial outbreaks, patterns of antimicrobial use, individual susceptibility and the length of hospitalization (the infection rates for *C. difficile* are reported to be around 10% after 2 weeks of hospitalization but may reach 50% after 4 or more weeks).

As regard to antibiotics used in the cases of study, we found that penicillin was used in all cases with positive *C. difficile* infection followed by cephalosporins (90.9%) and aminoglycosies (45.45%) although it was not statistically significant when compared with culture negative cases. Our observations were in accordance with the results of van der Kooi et al. (2008); King and Lager (2011); Kaneria and Paul (2012) who observed that previous treatment with cephalosporins is associated with high incidence of CDAD

Other study done by Takahashi et al. (2014) reported that the use of all types of intravenous antibiotics was significantly more prevalent in the CDI group than the control group. No significant differences were identified between the two groups with respect to oral antibiotic use. While our study showed no statistically significant differences between the two groups in all types of antibiotics used whether oral or intravenous.

In conclusion, Antibiotic therapy is the main risk factor of CDI in infants and children. The incidence of CDAD in the studied cases of infants and children admitted to our hospital 46.2% of the 26 patients with AAD. This high incidence may be attributed to injudicious use of broad spectrum antibiotics, defects in infection control measures that help in minimizing the nosocomial transmission of *C. difficile* among hospitalized patients. The asymptomatic carriage rate was 11.8%. All the cases had mild to moderate diarrhea. None of our studied cases had complications or mortality.

### **Acknowledgment**

The authors thank the staff members of Pediatrics and Microbiology departments, Tanta Faculty of Medicine for their valuable cooperation and support during the study. The authors also thank the participants themselves and their families.

### **References**

Beaulieu, M., Williamson, D., Pichette, G., Lachaine, J. 2007. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. *Infect. Control Hosp. Epidemiol.*, 28:1305–1307.

Center for Disease Control and Prevention, 2013. Antibiotic resistance threats in the United States. Available: <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>. Accessed 2015 Nov 8.

Cerquetti, M., Luzzi, I., Caprioli, A., Sebastianelli, A., Mastrantonio, P. 1995. Role of Clostridium difficile in childhood diarrhea. *Pediatr. Infect. Dis. J.*, 14(7): 598-603.

Ferri, F.F. 2010. Pseudomembranous colitis. In: Ferri FF (Ed.). *Ferri's Clinical Advisor*. 4<sup>th</sup> ed. Philadelphia (PA), Mosby Elsevier, pp. 323-328.

Gupta, U., Yadav, R.N. 1985. Clostridium difficile in hospital patients. *Indian J. Med. Res.*, 82: 398-401.

Hall, I.C., O'Toole, E. 1935. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, *Bacillus difficilis*. *Am. J. Dis. Child*, 49:390–402.

Hung, Y.P., Lee, J.C., Lin, H.J., Liu, H.C., Wu, Y.H., Tsai, P.J., Ko, W.C. 2015. Clinical impact of Clostridium difficile colonization. *J. Microbiol. Immunol. Infect.*, 48, 241-248.

Hurley, B.W., Nguyen, C.C. 2002. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. *Arch. Intern. Med.*, 162: 2177–84.

Jousimies-Somer, H.R., Summanen, P., Citron, D.M., Baron, E.J., Wexler, H.M., Finegold, S.M., Wadsworth, K.T.L. 2002. *Anaerobic Bacteriology Manual*. 6<sup>th</sup> ed. Belmont: Star Publishing Company.

Justin, S., Antony, B., Shenoy, K.V., Bolor, R. 2015. Prevalence of Clostridium Difficile Among Paediatric Patients in a Tertiary Care Hospital, Coastal Karnataka, South India. *Journal of Clinical and Diagnostic Research*, 9 (2): DC04-DC07.



- Kaneria, M.V., Paul, S. 2012. Incidence of *Clostridium difficile* associated diarrhoea in a tertiary care hospital. *J. Assoc. Physicians India.*, 60:26-8.
- Kim, J., Shaklee, J.F., Smathers, S., Prasad, P., Asti, L., Zoltanski, J., Dul, M., Nerandzic, M., Coffin, S.E., Toltzis, P., Zaoutis, T. 2012. Risk factors and outcomes associated with severe *Clostridium difficile* infection in children. *Pediatr. Infect. Dis. J.*, 31:134–138.
- King, R.N., Lager, S.L. 2011. Incidence of *Clostridium difficile* infections in patients receiving antimicrobial and acid-suppression therapy. *Pharmacotherapy*, 31:642–648.
- Knecht, H., Neulinger, S.C., Heinsen, F.A., Knecht, C., Schilhabel, A., Schmitz, R.A., Zimmermann, A., Santos, V.M., Ferrer, M., Rosenstiel, P.C., Schreiber, S., Friedrichs, A.K., Ott, S.J. 2014. Effects of b-Lactam Antibiotics and Fluoroquinolones on Human Gut Microbiota in Relation to *Clostridium difficile* Associated Diarrhea. *PLoS ONE* 9(2): e89417.
- Kyne, L., Hamel, M.B., Polavaram, R., Kelly, C.P. 2002. Health care costs and mortality associated with nosocomial diarrhea due to *Clostridium difficile*. *Clin. Infect. Dis.*, 34: 346–53.
- Larson, H.E., Price, A.B., Honour, P., Borriello, S.P. 1978. *Clostridium difficile* and the aetiology of pseudomembranous colitis. *Lancet*, 1:1063–1066.
- Levy, J. 2000. The effects of antibiotic use on gastrointestinal function. *Am Gastroenterol.*, 95, S8–S10.
- McFarland LV, (1998): Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. *Dig. Dis.*, 16:292-307.
- McFarland, L.V. 2007. Diarrhoea associated with antibiotic use. *British Medical Journal*, 335: 54-55.
- Niyogi, S.K., Dutta, P., Dutta, D., Mitra, U., Sikdar, S. 1991. *Clostridium difficile* and its cytotoxin in hospitalized children with acute diarrhea. *Indian Pediatr.*, 28(10): 1129-32.
- Pokorn, M., Radsel, A., Cizman, M., Jereb, M., Karner, P., Kalan, G. Grosek, S., Andlovic, A., Rupnik, M. 2008. Severe *Clostridium difficile*-associated disease in children. *Pediatr. Infect. Dis. J.*, 27:944–946.
- Sharland, M.C., Cant, A., Shingadia, D. 2011. *Clostridium difficile* infection. In: *Manual of childhood infections: the blue book*. Oxford, pp. 487–495.
- Takahashi, M., Mori, N., Bito, S. 2014. Multi-institution case-control and cohort study of risk factors for the development and mortality of *Clostridium difficile* infections in Japan. *BMJ Open.*, 4 (9): e005665.
- Turck, D., Bernet, J.P., Marx, J., Kempf, H., Giard, P., Walbaum, O., Lacombe, A., Rembert, F., Toursei, F., Bernasconi, P. 2003. Incidence and risk factors of oral antibiotic associated diarrhea in an outpatient pediatric population. *Journal of Pediatric gastroenterology And Nutrition*, 37: 22-26
- Vaishnavi, C., Kochhar, R., Bhasin, D.K., Thapa, B.R., Singh, K. 1999. Detection of *Clostridium difficile* toxin by an indigenously developed latex agglutination assay. *Trop. Gastroenterol.*, 20:33-5.
- Vaishnavi, C. 2010. Clinical spectrum & pathogenesis of *Clostridium difficile* associated diseases. *Indian J. Med. Res.*, 131:487-99.
- van der Kooi TI, Koningstein M, Lindemans A, Notermans DW, Kuijper E, van den Berg R. 2008. Antibiotic use and other risk factors at hospital level for outbreaks with *Clostridium difficile* PCR ribotype 027. *J. Med. Microbiol.*,

- 57:709–716.
- Voth, D.E., Ballard, J.D. 2005. Clostridium difficile toxins: mechanism of action and role in disease. *Clin. Microbiol. Rev.*, 18:247–263.
- Wilcox, M.H. 2003. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. *Best Pract. Res. Clin. Gastroenterol.*, 17: 475–93.
- Willis, A.T. 1977. Anaerobic Bacteriology: Clinical and Laboratory Practice. 3rd ed. London: Butterworth and Co (Publishers) Ltd.
- Wistrom, J., Norrby, S.R., Myhre, E., Ericsson, S., Granstorm, G., Lagergren, L., Englund, G., Nord, C.E., Svenungsson, B. 2001. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: A prospective study. *Antimicrob. Chemother.*, 47:43-50.
- Zilberberg, M.D., Shorr, A.F., Kollef, M.H. 2008<sub>a</sub>. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. *Emerg. Infect. Dis.*, 14:929–931.
- Zilberberg, M.D., Shorr, A.F., Kollef, M.H. 2008<sub>b</sub>. Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000–2005. *Pediatr. Infect. Dis. J.*, 27:1111–1113.

**How to cite this article:**

Marwa Ahmed Ali Abd El-Wahab, Ahmed Mohamed Naeem, Abd EL- Rahman Mohamed EL-Mashad and Nehad Refhat Mostafa Sallam. 2016. Antibiotic Associated Diarrhea and Incidence of Clostridium difficile Infection and Colonization in Infants and Children in Tanta University Hospital, Egypt. *Int.J.Curr.Microbiol.App.Sci*. 5(1): 576-585  
<http://dx.doi.org/10.20546/ijcmas.2016.501.059>